ABVC Biopharma Inc (ABVC) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
ABVC Biopharma Inc stock (ABVC) is currently trading at $1.13. ABVC Biopharma Inc PS ratio (Price-to-Sales) is 27.42. Analyst consensus price target for ABVC is $2.02. WallStSmart rates ABVC as Sell.
- ABVC PE ratio analysis and historical PE chart
- ABVC PS ratio (Price-to-Sales) history and trend
- ABVC intrinsic value — DCF, Graham Number, EPV models
- ABVC stock price prediction 2025 2026 2027 2028 2029 2030
- ABVC fair value vs current price
- ABVC insider transactions and insider buying
- Is ABVC undervalued or overvalued?
- ABVC Biopharma Inc financial analysis — revenue, earnings, cash flow
- ABVC Piotroski F-Score and Altman Z-Score
- ABVC analyst price target and Smart Rating
ABVC Biopharma Inc
📊 No data available
Try selecting a different time range
Smart Analysis
ABVC Biopharma Inc (ABVC) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in operating margin, revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
ABVC Biopharma Inc (ABVC) Key Strengths (2)
Keeps $376 of every $100 in revenue after operating costs
Revenue surging 104.50% year-over-year
Supporting Valuation Data
ABVC Biopharma Inc (ABVC) Areas to Watch (5)
Company is destroying shareholder value
Very expensive at 27.4x annual revenue
Very low institutional interest at 3.40%
Micro-cap company with very limited liquidity and high volatility
Fairly priced relative to book value
Supporting Valuation Data
ABVC Biopharma Inc (ABVC) Detailed Analysis Report
Overall Assessment
This company scores 34/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 10.0/10) while 5 fall into concern territory (avg 2.6/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Operating Margin, Revenue Growth. Profitability is solid with Operating Margin at 375.80%. Growth metrics are encouraging with Revenue Growth at 104.50%.
The Bear Case
The primary concerns are Return on Equity, Price/Sales, Institutional Own.. Some valuation metrics including Price/Sales (27.42), Price/Book (2.82) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -119.50%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -119.50% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 104.50% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Sales are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ABVC Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ABVC's Price-to-Sales ratio of 27.42x trades at a deep discount to its historical average of 286.77x (10th percentile). The current valuation is 100% below its historical high of 5589.67x set in Jan 2019, and 779% above its historical low of 3.12x in Jan 2015. Over the past 12 months, the PS ratio has compressed from ~41.0x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for ABVC Biopharma Inc (ABVC) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
ABVC Biopharma Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 797,920 with 105% growth year-over-year.
Key Findings
Revenue growing at 105% YoY, reaching 797,920. This pace significantly outperforms most BIOTECHNOLOGY peers.
Free cash flow is -587,582, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can ABVC Biopharma Inc maintain 105%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact ABVC Biopharma Inc.
Bottom Line
ABVC Biopharma Inc is a high-conviction growth story with revenue accelerating at 105% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 10:00:38 AM
About ABVC Biopharma Inc(ABVC)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
American BriVision (Holding) Corporation, a clinical-stage biopharmaceutical company, develops drugs and medical devices to meet unmet medical needs in the United States.